Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

The treatment of newly diagnosed chronic phase chronic myeloid leukemia (CML) with nilotinib has resulted in a higher rate of major molecular (MMR) and complete cytogenetic response (CCyR) at 12 months compared to imatinib but at a higher cumulative cost and increased risk of serious adverse events....

Descripción completa

Detalles Bibliográficos
Autores principales: Ibrahim, Ali, Moukalled, Nour, Mahfouz, Rami, El Cheikh, Jean, Bazarbachi, Ali, Abou Dalle, Iman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358791/
https://www.ncbi.nlm.nih.gov/pubmed/35950205
http://dx.doi.org/10.1007/s44228-022-00001-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358791/
https://www.ncbi.nlm.nih.gov/pubmed/35950205
http://dx.doi.org/10.1007/s44228-022-00001-x

Ejemplares similares